Table 1 Baseline characteristics
Baseline characteristics | Group A N = 22 | Group B N = 16 pts | p-value |
|---|---|---|---|
Age (years old) (Mean ± SD) | 72.00 ± 9.07 | 70.25 ± 7.28 | 0.53 |
Number patients that received treatment (n, %) | 22/29 (75.86%) | 16/37 (43.24%) | 0.008 |
Gender (male) (n, %) | 16/22 (72.73%) | 14/16 (87.50%) | 0.43 |
Number of successful attempts of treatment (n, %) | 23/32 (71.88%) | 17/39 (43.59%) | 0.02 |
Cirrhosis (n, %) | 20/22 (90.91%) | 12/16 (75%) | 0.22 |
Cirrhosis type (n, %) | 0.77 | ||
Alcohol | 10/20 (50%) | 6/12 (50%) | 1.00 |
HBV | 1/20 (5%) | 1/12 (8.33%) | 1.00 |
HCV | 3/20 (15%) | 3/12 (25%) | 0.65 |
Other (combining factors) | 6/20 (30%) | 2/12 (16.67%) | 0.68 |
Child–Pugh (n, %) | 1.00 | ||
A | 16/18 (88.89%) | 11/12 (91.67%) | |
B | 2/18 (11.11%) | 1/12 (8.33%) | |
ECOG score (n, %) | 1.00 | ||
0 | 17/22 (77.27%) | 12/16 (75%) | |
1 | 5/22 (22.73%) | 4/16 (25%) | |
Previous treatment (n, %) | 0.049 | ||
No previous treatment | 11/22 (50%) | 13/16 (81.25%) | |
At least one previous treatment | 11/22 (50%) | 3/16 (18.75%) | |
Previous treatment type (n, %) | 0.47 | ||
SIRT/TACE | 5/11 (45.45%) | 2/3 (66.67%) | |
Systemic | 1/11 (9.09%) | 1/3 (33.33%) | |
Surgery | 1/11 (9.09%) | 0/3 (0%) | |
Multiples combination treatments | 4/11 (36.33%) | 0/3 (0%) | |
HCC-tumor load (n, %) | |||
Infiltrative | 2/22 (9.09%) | 2/16 (12.50%) | 1.00 |
Satellite | 9/22 (40.91%) | 5/16 (31.25%) | 0.54 |
Ascites | 1/22 (4.55%) | 1/16 (6.25%) | 1.00 |
Portal vein invasion | 6/22 (27.27%) | 4/16 (25.00%) | 1.00 |
Portal hypertension | 11/22 (50.00%) | 4/16 (25.00%) | 0.12 |
Bile duct dilation | 4/22 (18.18%) | 4/16 (25.00%) | 0.70 |
Extrahepatic spread | 0/22 (0%) | 2/16 (12.50%) | 0.17 |
Number of nodules (Median [min–max] HCC) | 1 [1–10] | 1 [1–3] | 0.054 |
Diameter of biggest nodule (mm) (Median [min–max]) | 52 [17–163] | 65 [13–160] | 0.71 |
AFP Score (n, %) | 0.74 | ||
< 100 | 14/22 (63.64%) | 11/16 (68.75%) | |
≥ 100 | 8/22 (36.36%) | 5/16 (31.25%) | |
BCLC (n, %) | 1.00 | ||
A | 2/22 (9.09%) | 2/16 (12.50%) | |
B | 14/22 (53.64%) | 10/16 (62.50%) | |
C | 6/22 (27.27%) | 4/16 (25.00%) | |
Treatment characteristics | 0.26 | ||
Lobar | 15/22 (68.18%) | 8/16 (50.00%) | |
Selective | 7/22 (31.82%) | 8/16 (50.00%) | |